ESR1 and breast cancer: Therefore, the importance of SRCs as therapeutic targets cannot be over-estimated, particularly as an opportunity for moving beyond the existing tool-box of BC endocrine therapy, chiefly in cases of acquired resistance which is frequently associated with advanced stages of the disease and gain-of-function mutations in ERα.